Compare Annaly Capital Management, Inc. (NLY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Novo Nordisk A/S — how do they compare? Annaly Capital Management, Inc. trades at $22.9 (market cap $16.63B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 13.3× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.22%). Which is the better fit depends on your goals.
| NLY | NVO | |
|---|---|---|
Market Cap | $16.63B | $220.53B |
Sector | Financials | Health |
52-Week High | $24.40 | $71.70 |
52-Week Low | $19.96 | $35.29 |
Dividend Yield | 13.22% | 3.63% |
Enterprise Value | — | $239.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
